-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Alnylam Pharmaceuticals, Lowers Price Target to $345

Benzinga·10/08/2026 14:19:59
Listen to the news
RBC Capital analyst Luca Issi maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform and lowers the price target from $350 to $345.